

Oliver Rath

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1430660/publications.pdf>

Version: 2024-02-01

25
papers

4,157
citations

361045

20
h-index

610482

24
g-index

25
all docs

25
docs citations

25
times ranked

8420
citing authors

#	ARTICLE	IF	CITATIONS
1	MAP kinase signalling pathways in cancer. <i>Oncogene</i> , 2007, 26, 3279-3290.	2.6	2,473
2	Kinesins and cancer. <i>Nature Reviews Cancer</i> , 2012, 12, 527-539.	12.8	412
3	Positive- and negative-feedback regulations coordinate the dynamic behavior of the Ras-Raf-MEK-ERK signal transduction pathway. <i>Journal of Cell Science</i> , 2009, 122, 425-435.	1.2	162
4	A hidden oncogenic positive feedback loop caused by crosstalk between Wnt and ERK Pathways. <i>Oncogene</i> , 2007, 26, 4571-4579.	2.6	141
5	Functional Roles of Multiple Feedback Loops in Extracellular Signal-Regulated Kinase and Wnt Signaling Pathways That Regulate Epithelial-Mesenchymal Transition. <i>Cancer Research</i> , 2010, 70, 6715-6724.	0.4	138
6	Structural Basis for Inhibition of Eg5 by Dihydropyrimidines: Stereoselectivity of Antimitotic Inhibitors Enastron, Dimethylenastron and Fluorastrol. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 5676-5683.	2.9	126
7	Raf Kinase Inhibitor Protein RKIP Enhances Signaling by Glycogen Synthase Kinase-3 β . <i>Cancer Research</i> , 2011, 71, 1334-1343.	0.4	124
8	RAF kinase inhibitory protein (RKIP) modulates cell cycle kinetics and motility. <i>Molecular BioSystems</i> , 2011, 7, 928-941.	2.9	58
9	Relocation of AuroraB and Survivin from Centromeres to the Central Spindle Impaired by a Kinesin-specific MKLP2 Inhibitor. <i>Angewandte Chemie - International Edition</i> , 2010, 49, 8228-8231.	7.2	54
10	The RKIP (Raf-1 Kinase Inhibitor Protein) conserved pocket binds to the phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated activated phosphorylation of MEK. <i>Cellular Signalling</i> , 2008, 20, 935-941.	1.7	49
11	Patient-derived cell models as preclinical tools for genome-directed targeted therapy. <i>Oncotarget</i> , 2015, 6, 25619-25630.	0.8	48
12	Structural Insights into a Unique Inhibitor Binding Pocket in Kinesin Spindle Protein. <i>Journal of the American Chemical Society</i> , 2013, 135, 2263-2272.	6.6	44
13	Regulation of RKIP binding to the N-region of the Raf-1 kinase. <i>FEBS Letters</i> , 2006, 580, 6405-6412.	1.3	43
14	Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia. <i>Leukemia</i> , 2012, 26, 1842-1849.	3.3	38
15	Regulation of human myoblast differentiation by PEBP4. <i>EMBO Reports</i> , 2009, 10, 278-284.	2.0	37
16	Triphenylbutanamines: Kinesin Spindle Protein Inhibitors with in Vivo Antitumor Activity. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 1511-1525.	2.9	37
17	Optimized Trityl-cysteine-Based Inhibitors of Kinesin Spindle Protein with Potent in Vivo Antitumor Activity in Lung Cancer Xenograft Models. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 1878-1893.	2.9	35
18	LIM kinase inhibitors disrupt mitotic microtubule organization and impair tumor cell proliferation. <i>Oncotarget</i> , 2015, 6, 38469-38486.	0.8	34

#	ARTICLE	IF	CITATIONS
19	Extracellular Signal-Regulated Kinase Regulates RhoA Activation and Tumor Cell Plasticity by Inhibiting Guanine Exchange Factor H1 Activity. <i>Molecular and Cellular Biology</i> , 2013, 33, 4526-4537.	1.1	30
20	Investigating dynamics of inhibitory and feedback loops in ERK signalling using power-law models. <i>Molecular BioSystems</i> , 2010, 6, 2174.	2.9	24
21	Doing the methylene shuffle – Further insights into the inhibition of mitotic kinesin Eg5 with S-trityl l-cysteine. <i>European Journal of Medicinal Chemistry</i> , 2012, 54, 483-498.	2.6	20
22	Depsidones from Lichens as Natural Product Inhibitors of M-Phase Phosphoprotein 1, a Human Kinesin Required for Cytokinesis. <i>Journal of Natural Products</i> , 2016, 79, 1576-1585.	1.5	16
23	BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells. <i>Translational Oncology</i> , 2016, 9, 197-202.	1.7	10
24	Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor-Resistant Clear Cell Renal Cell Carcinoma. <i>Translational Oncology</i> , 2017, 10, 304-310.	1.7	4
25	c-Myc is required for transformation of FDC-P1 cells by EGFRvIII. <i>FEBS Letters</i> , 2007, 581, 2549-2556.	1.3	0